Position
MPM BIOIMPACT LLC in Dyne Therapeutics, Inc.
Back to the book · All holders of DYN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$2.01M$19.56 → $18.13
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.41M | $27.5M | — | — | — | 3.1% |
| Q1 2026 | 1.41M | $25.5M | $18.13 | −$2.01M | $50.1K | 2.0% |